Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer
- Conditions
- Uterine Cervical NeoplasmsCervical CancerUterine Cervical Cancer
- Registration Number
- NCT03229187
- Lead Sponsor
- Huazhong University of Science and Technology
- Brief Summary
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies.
However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments.
This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 240
Inclusion Criteria
- Untreated cervical cancer with FIGO stage Ib-IIb
- Measurable lesions
- Possible to radical hysterectomy
- Age: 18 and older
- Karnofsky Performance Status≥ 70.
- WBC > 3,000/mm³, Hb > 9.0g/dl, Platelet > 100,000 /mm³, SGOT/SGPT < 60 IU/L, T-Bil < 1.5 mg/dL, Cr < 1.2 mg/dL, PaO2 > 80 torr, normal ECG
- Written informed consent
Exclusion Criteria
- Previous history of cancer
- Patients with previous treatment
- Patients without information of clinical risk factors
- Patients who have active infection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The clinical response to neoadjuvant chemotherapy 1 to 3 months clinical response（tumor size）
- Secondary Outcome Measures
Name Time Method The pathological response to neoadjuvant chemotherapy 1 to 3 months pathological response（\<3 mm or not）
Trial Locations
- Locations (1)
Tongji Hospital
🇨🇳Wuhan, Hubei, China